Results

1–10 of 21 results for Complement

ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design andRationale Informed by Outcomes From ARCHER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2025
Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related MacularDegeneration From Real-World Data
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2025
Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD
Josh Wallsh
Annual Meeting Talks
2025
CD 46 is a Potent Complement Cofactor as Part of a Clinical Strategy for Geographic Atrophy
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2026
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Intravitreal ANX007: Results of the ARCHER Study
Jeffrey S. Heier, MD
Annual Meeting Talks
2023
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Using New Sialic Acid-Coated Nanoparticles
Carl D. Regillo, MD
Annual Meeting Talks
2023
Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024
First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
Omer Trivizki, MD, MBA
Updates from the Field
2025
Inhibition of C1q Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy
Patrick Dewey Williams, MD
Annual Meeting Talks
2022